Markets / Results moves / Mankind Pharma
How much options priced in before each of Mankind Pharma's quarterly results, how much the share actually moved, and what to expect for the next results.
Mankind Pharma share price, technicals and fundamentals › · How to read this page ›
Sales ₹4,338 cr (+17.3% from a year ago), net profit ₹711 cr (+39.1%), EPS ₹17.23. The share opened +2.01% higher.
Usual move after results: ±4.86% (average size of the last 4). The move is the change on the day the results reached the market: the results day if they came out before 15:30, otherwise the next trading day.
| Quarter | Reaction day | Opening gap | Day's move |
|---|---|---|---|
| Q2 FY27 | 27 Oct 2026 | +2.01% | +8.24% |
| Q1 FY27 | 31 Jul 2026 | +1.09% | −4.13% |
| Q4 FY26 | 20 May 2026 | +0.34% | +3.66% |
| Q3 FY26 | 4 Feb 2026 | +1.68% | −3.39% |
| Q2 FY26 | 7 Nov 2025 | −2.56% | −2.05% |
| Q1 FY26 | 1 Aug 2025 | +0.10% | −0.04% |
| Q4 FY25 | 22 May 2025 | −3.22% | −3.64% |
| Q3 FY25 | 24 Jan 2025 | −2.85% | −4.86% |
"Options priced in" exists from October 2026, when the site started saving straddles; every new result adds it.
In the days before results this page shows live what options price in, against the usual move.
Moves from NSE daily prices; results dates from the company's NSE filings; what options priced in from our saved straddle charts (from October 2026). Information only, not investment advice.
Mankind Pharma rose 8.24% on 27 Oct 2026, the day its Q2 FY27 results (out 26 Oct 2026) reached the market. Options had priced in a move of about ±7.68%.
About ±4.86% on average over its last 4 results.
Its Dec quarter results are expected around 27 Jan to 10 Feb 2027, based on last year's date (3 Feb 2026).